Human Reproduction, Vol. 16, No. 10, 2098-2102,
October 2001
© 2001 European Society of Human Reproduction and Embryology
Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation
Centre for Reproductive Biology, University of Edinburgh, 37 Chalmers Street, Edinburgh EH3 9ET, UK
BACKGROUND: Gemeprost and misoprostol are two of the most widely used prostaglandins in combination with mifepristone for medical abortion in early pregnancy. However, the efficacy and side-effects of those two drugs given vaginally have not been assessed in a randomized trial. METHODS: Randomized double-blind controlled trial involving 999 women undergoing an abortion at gestational age 
63 days who received either 0.5 mg gemeprost (group I, n = 499) or 800 µg misoprostol (group II, n = 500) vaginally ~48 h after taking 200 mg mifepristone by mouth. The rate of complete abortion and the side-effects were compared between the groups. RESULTS: A total of 89 cases was excluded from full analysis of outcome because either they aborted after mifepristone alone (n = 2), had an ectopic pregnancy (n = 1), or because the outcome was uncertain as they failed to attend their follow-up appointment (n = 86). The rate of complete abortion was very high (>95%) in both groups but significantly higher after treatment with misoprostol than with gemeprost [436/453 (98.7%) versus 451/457 (96.2%), P = 0.019, difference 2.5%, confidence interval 0.4–4.7%] and there were fewer ongoing pregnancies (n = 1 versus n = 8, P < 0.018). Surgical intervention rose significantly with gestation in women who received gemeprost (P < 0.03) but not with misoprostol. The incidence of side-effects such as diarrhoea (13.7 versus 16.4%) and vomiting (27.8 versus 29.7%) was similar in women who received misoprostol or gemeprost respectively, as was the duration and amount of bleeding. CONCLUSIONS: (i) Both regimens using a reduced dose of mifepristone are highly effective methods of inducing abortion in early pregnancy; (ii) vaginal misoprostol is the preferred prostaglandin because it is it is associated with fewer failures than low-dose gemeprost, particularly at gestation 
49 days.
Key words: gemeprost/medical abortion/mifepristone/misoprostol
1 To whom correspondence should be addressed. E-mail: dtbaird{at}ed.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Lalitkumar, M. Bygdeman, and K. Gemzell-Danielsson Mid-trimester induced abortion: a review Hum. Reprod. Update, January 1, 2007; 13(1): 37 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rorbye, M. Norgaard, and L. Nilas Medical versus surgical abortion: comparing satisfaction and potential confounders in a partly randomized study Hum. Reprod., March 1, 2005; 20(3): 834 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rorbye, M. Norgaard, and L. Nilas Prediction of late failure after medical abortion from serial {beta}-hCG measurements and ultrasonography Hum. Reprod., January 1, 2004; 19(1): 85 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Tang, S. W.H. Lee, and P. C. Ho A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone Hum. Reprod., November 1, 2002; 17(11): 2865 - 2868. [Abstract] [Full Text] [PDF]
|
|